[Transcutaneous oximetry in smokers with moderate hypertension and peripheral arterial disease treated with amlodipine and defibrotide, also with total smoking cessation].
To evaluate the hemorheological influence on oxygen release after a period of 4 months of suspension from smoking and of antihypertensive treatment with amlodipine 10 mg o.d. and defibrotide 400 mg o.d. we have studied 14 smokers with II moderate hypertension (according to the World Health Organization) with hypertensive retinopathy II and slight left ventricular hypertrophy and II stage type a peripheral arterial disease according to Leriche-Fontaine classification. The total suspension for a period of 4 months from smoking associated with a Ca-antagonist such as amlodipine and an hemorheological, antithrombotic drug such as defibrotide together could bring about an improvement on the treatment of hypertension and a notable reduction in the risks linked to the complications found in hypertensives with PAOD II type a.
Cicco
G
G
Universita degli Studi - Bari, DIMO Sezione di Medicina Interna, Centro Ipertensione Arteriosa.
Dolce
E
E
Gigante
G
G
Pirrelli
A
A
D017311:Amlodipine / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001785:Blood Gas Monitoring, Transcutaneous; D001809:Blood Viscosity; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000628:therapy*; D017379:Hypertrophy, Left Ventricular / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000628:therapy*; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use*; D012907:Smoking / Q000009:adverse effects*; D016540:Smoking Cessation
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D011089:Polydeoxyribonucleotides; D017311:Amlodipine; C036901:defibrotide